JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mabley, J. G.
Right arrow Articles by Szabó, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mabley, J. G.
Right arrow Articles by Szabó, C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes Type 1
Hazardous Substances DB
*NICOTINE
*NICOTINE TARTRATE

Vol. 300, Issue 3, 876-881, March 2002

Nicotine Reduces the Incidence of Type I Diabetes in Mice

J. G. Mabley, P. Pacher, G. J. Southan, A. L. Salzman and C. Szabó

Inotek Corporation, Beverly, Massachusetts

Nicotine has been previously shown to have immunosuppressive actions. Type I diabetes is an autoimmune disease resulting from the specific destruction of the insulin-producing pancreatic beta -cells. Thus, we hypothesized that nicotine may exert protective effects against type I diabetes. The multiple low-dose streptozotocin (MLDS)-induced model and spontaneous nonobese diabetic (NOD) mouse model of type I diabetes were used to assess whether nicotine could prevent this autoimmune disease. Blood glucose levels, diabetes incidence, pancreas insulin content, and cytokine levels were measured in both models of diabetes, both to asses the level of protection exerted by nicotine and to further investigate its mechanism of action. Nicotine treatment reduced the hyperglycemia and incidence of disease in both the MLDS and NOD mouse models of diabetes. Nicotine also protected against the diabetes-induced decrease in pancreatic insulin content observed in both animal models. The pancreatic levels of the Th1 cytokines interleukin (IL)-12, IL-1, tumor necrosis factor (TNF)-alpha , and interferon (IFN)-gamma were increased in both MLDS-induced and spontaneous NOD diabetes, an effect prevented by nicotine treatment. Nicotine treatment increased the pancreatic levels of the Th2 cytokines IL-4 and IL-10. Nicotine treatment reduces the incidence of type I diabetes in two animal models by changing the profile of pancreatic cytokine expression from Th1 to Th2.

0022-3565/02/3003-0876$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Immunol.Home page
F.-D. Shi, W.-H. Piao, Y.-P. Kuo, D. I. Campagnolo, T. L. Vollmer, and R. J. Lukas
Nicotinic Attenuation of Central Nervous System Inflammation and Autoimmunity
J. Immunol., February 1, 2009; 182(3): 1730 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
B. Mravec
Letter To the Editor: Autonomic dysfunction in autoimmune diseases: consequence or cause?
Lupus, September 1, 2007; 16(9): 767 - 768.
[PDF]

Home page
 J. Leukoc. Biol.Home page
M.-R. Blanchet, A. Langlois, E. Israel-Assayag, M.-J. Beaulieu, C. Ferland, M. Laviolette, and Y. Cormier
Modulation of eosinophil activation in vitro by a nicotinic receptor agonist
J. Leukoc. Biol., May 1, 2007; 81(5): 1245 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M.-R. Blanchet, E. Israel-Assayag, P. Daleau, M.-J. Beaulieu, and Y. Cormier
Dimethyphenylpiperazinium, a nicotinic receptor agonist, downregulates inflammation in monocytes/macrophages through PI3K and PLC chronic activation
Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L757 - L763.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M-R. Blanchet, E. Israel-Assayag, and Y. Cormier
Modulation of airway inflammation and resistance in mice by a nicotinic receptor agonist
Eur. Respir. J., July 1, 2005; 26(1): 21 - 27.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R.-H. Liu, M. Mizuta, and S. Matsukura
The Expression and Functional Role of Nicotinic Acetylcholine Receptors in Rat Adipocytes
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 52 - 58.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M.-R. Blanchet, E. Israel-Assayag, and Y. Cormier
Inhibitory Effect of Nicotine on Experimental Hypersensitivity Pneumonitis In Vivo and In Vitro
Am. J. Respir. Crit. Care Med., April 15, 2004; 169(8): 903 - 909.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.